Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia

BACKGROUND: Continuous antipsychotic therapy is recommended as part of long-term maintenance treatment of schizophrenia, and gaps in antipsychotic treatment have been associated with increased risks of relapse and rehospitalization. Because the use of long-acting injectable (LAI) antipsychotics may...

Descripción completa

Detalles Bibliográficos
Autores principales: Lauriello, John, Weiden, Peter J., Gleeson, Carole D., Shah, Ankit, Boulanger, Luke, Jariwala-Parikh, Krutika, Hedgeman, Elizabeth, O’Sullivan, Amy K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478765/
https://www.ncbi.nlm.nih.gov/pubmed/34546558
http://dx.doi.org/10.1007/s40263-021-00849-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478765/
https://www.ncbi.nlm.nih.gov/pubmed/34546558
http://dx.doi.org/10.1007/s40263-021-00849-2

Ejemplares similares